Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phase 2 study of nilotinib as third-line therapy for patients with gastrointestinal stromal tumor.

Cancer - 15 Oct 2011

Sawaki Akira, Nishida Toshirou, Doi Toshihiko, Yamada Yasuhide, Komatsu Yoshito, Kanda Tatsuo, Kakeji Yoshihiro, Onozawa Yusuke, Yamasaki Makoto, Ohtsu Atsushi

Abstract excerpt

BACKGROUND: Patients with gastrointestinal stromal tumors (GISTs) resistant to both imatinib and sunitinib have a poor prognosis and few therapeutic options. In this study, the efficacy and safety of nilotinib (AMN107) as a third-line therapy for patients with GISTs was evaluated. METHODS: A sing...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Drug Administration Schedule
Share to Gastrointestinal Stromal Tumors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Imatinib Mesylate

Share to Pyrroles

Share to Receptor, Platelet-Derived Growth Factor alpha

Share to Salvage Therapy

Share to Sunitinib

Source

Identifiers

PMID: 21456006
DOI: 10.1002/cncr.26120

Genes

KIT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-21456006-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phase 2 study of nilotinib as third-line therapy for patients with gastrointestinal stromal tumor.PMID 21456006Read ↗

Efficacy evaluation of nilotinib treatment in different genomic subtypes of gastrointestinal stromal tumors: A meta-analysis and systematic review.Semantic proximity Read ↗

Evaluation of nilotinib in advanced GIST previously treated with imatinib and sunitinib.Semantic proximity Read ↗

Patterns of care, prognosis, and survival in patients with metastatic gastrointestinal stromal tumors (GIST) refractory to first-line imatinib and second-line sunitinib.Semantic proximity Read ↗

Treatment of gastrointestinal stromal tumor after imatinib and sunitinib.Semantic proximity Read ↗

An updated review of the treatment landscape for advanced gastrointestinal stromal tumors.Semantic proximity Read ↗

A prospective multicenter phase II study on the efficacy and safety of dasatinib in the treatment of metastatic gastrointestinal stromal tumors failed by imatinib and sunitinib and analysis of NGS in peripheral blood.Semantic proximity Read ↗

Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors.Semantic proximity Read ↗

Sunitinib, a multitargeted tyrosine kinase inhibitor, in the management of gastrointestinal stromal tumor.Semantic proximity Read ↗

Sunitinib for Taiwanese patients with gastrointestinal stromal tumor after imatinib treatment failure or intolerance.Semantic proximity Read ↗

Activity of Anlotinib in the Second-Line Therapy of Metastatic Gastrointestinal Stromal Tumors: A Prospective, Multicenter, In Vitro Study.Semantic proximity Read ↗

Sorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: a phase II study of Korean gastrointestinal stromal tumors study group.Semantic proximity Read ↗

Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.